Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo...

Dr Joshua Sabari and Dr Anna Minchom

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal...

Prof Daniel Catenacci - University of Chicago, Chicago, USA

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )

Clinical trials participation is directly influenced by the information...

Dr Daniel Vorobiof - Belong.Life, New York, USA

Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with...

Dr Jonathan Spicer - McGill University, Montreal, Canada

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )

Incidence and trends of HPV-related cancers in the United States

Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Incidence and trends of HPV-related cancers in the United States ( Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Dr Neal Shore and Prof Oliver Sartor

ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )

More from ecancer